Carfilzomib-Lenalidomide-Dexa, Lenalidomide in Smoldering, Newly Diagnosed Myeloma

Share this content:
Carfilzomib-lenalidomide-dexamethasone demonstrates high rates of minimal residual disease negativity in multiple myeloma.
Carfilzomib-lenalidomide-dexamethasone demonstrates high rates of minimal residual disease negativity in multiple myeloma.

Therapy with carfilzomib-lenalidomide-dexamethasone demonstrates high rates of minimal residual disease negativity in newly diagnosed multiple myeloma (NDMM), which equals longer progression-free survival in patients achieving MRD negativity.

The combination also demonstrates efficacy in high-risk smoldering multiple myeloma (SMM), according to an article published online ahead of print in the journal JAMA Oncology.

A clinical and correlative pilot study at the National Institutes of Health Clinical Center was performed to assess the safety and efficacy of carfilzomib-lenalindomide-dexamethasone therapy on NDMM and SMM. A total of 57 patients were enrolled (45 with NDMM, 12 high-risk SMM).

Patients received eight 28-day cycles of carfilzominb 20/36 mg/m2 on days 1, 2, 8, 9, 15, and 16; lenalidomide 25 mg on days 1 through 21; and dexamethasone 20/10 mg (cycles 1-4/5-8) on days 1, 2, 8, 9, 15, 16, 22, and 23. Those who achieved at least stable response then received 24 cycles of extended lenalidomide. Median follow-up was 17.3 months for NDMM and 15.9 months for SMM.

RELATED: Bortezomib, Dexamethasone Seems Preferred for Transplant-Ineligible Myeloma

None of the NDMM patients experienced grade 3 or higher neuropathy, one of the study's primary endpoints. All of the SMM patients experienced lymphopenia, and 92% experienced gastrointestinal disorders. All patients with SMM achieved at least a very good partial response rate.

Out of the 28 NDMM patients and the 12 SMM patients who achieved at least a near-complete response, MRD negativity was found in all NDMM patients, 92% in patients with SMM (multiparametric flow cytometry), 67% of 21 patients with NDMM, and 75% in 12 SMM patients (next-generation sequencing), respectively.

Reference

  1. Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. 2015. JAMA Onc [epub online ahead of print]. doi: 10.1001/jamaoncol.2015.2010.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters